

Basic science: (February 2009)

1. Ang EZF, Nguyen HT, Sim HL, Putti TC, Lim LHK. Annexin-1 regulates growth arrest induced by high levels of estrogen in MCF-7 breast cancer cells. *Mol Cancer Res* 2009; **7**: 266–274.
2. Beck AH, Espinosa I, Edris B, Li R, Montgomery K, Zhu S, Varma S, Marinelli RJ, van de Rijn M, West RB. The macrophage colony-stimulating factor 1 response signature in breast carcinoma. *Clin Cancer Res* 2009; **15**: 778–787.
3. Brerner TM, Jacquemier J, Charafe-Jauffret E, Viens P, Birnbaum D, Linke SP. Prognostic marker profile to assess risk in stage I–III hormone receptor-positive breast cancer patients. *Int J Cancer* 2009; **124**: 896–904.
4. Chlebowski RT, Kuller LH, Prentice RL, Stefanick ML, Manson JE, Gass M, Aragaki AK, Ockene JK, Lane DS, Sarto GE, Rajkovic A, Schenken R, Hendrix SL, Ravdin PM, Rohan TE, Yasmeen S, Anderson G. Breast cancer after use of estrogen plus progestin in postmenopausal women. *N Engl J Med* 2009; **360**: 573–587.
5. Connors SK, Balusu R, Kundu CN, Jaiswal AS, Gairola CG, Narayan S. C/EBP β -mediated transcriptional regulation of bcl-xl gene expression in human breast epithelial cells in response to cigarette smoke condensate. *Oncogene* 2009; **28**: 921–932.
6. de Gonzalez A, Berg CD, Visvanathan K, Robson M. Estimated risk of radiation-induced breast cancer from mammographic screening for young BRCA mutation carriers. *J Natl Cancer Inst* 2009; **101**: 205–209.
7. Ford CE, Ekstroem EJ, Andersson T. Wnt-5a signaling restores tamoxifen sensitivity in estrogen receptor-negative breast cancer cells. *Proc Natl Acad Sci U S A* 2009; **106**: 3919–3924.
8. Generali D, Bates G, Berruti A, Brizzi MP, Campo L, Bonardi S, Bersiga A, Allevi G, Milani M, Aguggini S, Dogliotti L, Banha AH, Harris AL, Bottini A, Fox SB. Immunomodulation of FOXP3(+) regulatory t cells by the aromatase inhibitor letrozole in breast cancer patients. *Clin Cancer Res* 2009; **15**: 1046–1051.
9. Gomes EM, Rodrigues MS, Phadke AP, Butcher LD, Starling C, Chen SL, Chang DK, Hernandez-Alcoceba R, Newman JT, Stone MJ, Tong AW. Antitumor activity of an oncolytic adenoviral-CD40 ligand (CD154) transgene construct in human breast cancer cells. *Clin Cancer Res* 2009; **15**: 1317–1325.
10. Gonzalez ME, Li X, Toy K, DuPrie M, Ventura AC, Banerjee M, Ljungman M, Merajver SD, Kleer CG. Downregulation of EZH2 decreases growth of estrogen receptor-negative invasive breast carcinoma and requires BRCA1. *Oncogene* 2009; **28**: 843–853.
11. Guler G, Huebner K, Himmetoglu C, Jimenez RE, Costinean S, Volinia S, Pilarski RT, Hayran M, Shapiro CL. Fragile histidine triad protein, WW domain-containing oxidoreductase protein Wwox, and activator protein 2 γ expression levels correlate with basal phenotype in breast cancer. *Cancer* 2009; **115**: 899–908.
12. Holm C, Kok M, Michalides R, Fles R, Koornstra RHT, Wesseling J, Hauptmann M, Neefjes J, Peterse JL, Stal O, Landberg G, Linn SC. Phosphorylation of the oestrogen receptor α at serine 305 and prediction of tamoxifen resistance in breast cancer. *J Pathol* 2009; **217**: 372–379.
13. Hong SW, Kim CJ, Park WS, Shin JS, Lee SD, Ko SG, Jung SI, Park IC, An SK, Lee WK, Lee WJ, Jin DH, Lee MS. p34(SEI-1) inhibits apoptosis through the stabilization of the x-linked inhibitor of apoptosis protein: p34(SEI-1) as a novel target for anti-breast cancer strategies. *Cancer Res* 2009; **69**: 741–746.
14. Hu M, Peluffo G, Chen H, Gelman R, Schnitt S, Polyak K. Role of COX-2 in epithelial-stromal cell interactions and progression of ductal carcinoma in situ of the breast. *Proc Natl Acad Sci U S A* 2009; **106**: 3372–3377.
15. Jin CY, Yang YA, Anver MR, Morris N, Wang XC, Zhang YE. Smad ubiquitination regulatory factor 2 promotes metastasis of breast cancer cells by enhancing migration and invasiveness. *Cancer Res* 2009; **69**: 735–740.

16. Klinakis A, Szabolcs M, Chen GY, Xuan SH, Hibshoosh H, Efstratiadis A. Igf1r as a therapeutic target in a mouse model of basal-like breast cancer. *Proc Natl Acad Sci U S A* 2009; **106**: 2359–2364.
17. Lee JY, Kang MB, Jang SH, Qian T, Kim HJ, Kim CH, Kim Y, Kong G. Id-1 activates Akt-mediated Wnt signaling and p27(Kip1) phosphorylation through PTEN inhibition. *Oncogene* 2009; **28**: 824–831.
18. Lu J, Tan M, Huang WC, Li P, Guo H, Tseng LM, Su XH, Yang WT, Treekitkarnmongkol W, Andreeff M, Symmans F, Yu D. Mitotic deregulation by survivin in ErbB2-overexpressing breast cancer cells contributes to taxol resistance. *Clin Cancer Res* 2009; **15**: 1326–1334.
19. Malone JL, Nelson AC, Lieberman R, Anderson S, Holt JT. Oestrogen-mediated phosphorylation and stabilization of BRCA2 protein in breast. *J Path* 2009; **217**: 380–388.
20. McGlynn LM, Kirkegaard T, Edwards J, Tovey S, Cameron D, Twelves C, Bartlett JMS, Cooke TG. Ras/Raf-1/MAPK pathway mediates response to tamoxifen but not chemotherapy in breast cancer patients. *Clin Cancer Res* 2009; **15**: 1487–1495.
21. Ostrow KL, Park HL, Hoque MO, Kim MS, Liu JW, Argani P, Westra W, Van Criekinge W, Sidransky D. Pharmacologic unmasking of epigenetically silenced genes in breast cancer. *Clin Cancer Res* 2009; **15**: 1184–1191.
22. Piening BD, Wang P, Subramanian A, Paulovich AG. A radiation-derived gene expression signature predicts clinical outcome for breast cancer patients. *Radiat Res* 2009; **171**: 141–154.
23. Pylayeva Y, Gillen KM, Gerald W, Beggs HE, Reichardt LF, Giancotti FG. Ras- and PI3K-dependent breast tumorigenesis in mice and humans requires focal adhesion kinase signaling. *J Clin Invest* 2009; **119**: 252–266.
24. Ramaswamy B, Majumder S, Roy S, Ghoshal K, Kutay H, Datta J, Younes M, Shapiro CL, Motiwala T, Jacob ST. Estrogen-mediated suppression of the gene encoding protein tyrosine phosphatase PTPRO in human breast cancer: mechanism and role in tamoxifen sensitivity. *Mol Endocrinol* 2009; **23**: 176–187.
25. Sankpal NV, Willman MW, Fleming TP, Mayfield JD, Gillanders WE. Transcriptional repression of epithelial cell adhesion molecule contributes to p53 control of breast cancer invasion. *Cancer Res* 2009; **69**: 753–757.
26. Schild-Hay LJ, Leil TA, Divi RL, Olivero OA, Weston A, Poirier MC. Tamoxifen induces expression of immune response-related genes in cultured normal human mammary epithelial cells. *Cancer Res* 2009; **69**: 1150–1155.
27. Sotgia F, Casimiro MC, Bonuccelli G, Liu MR, Whitaker-Menezes D, Er O, Daumer KM, Mercier I, Witkiewicz AK, Minetti C, Capozza F, Gormley M, Quong AA, Rui H, Frank PG, Milliman JN, Knudsen ES, Zhou J, Wang CG, Pestell RG, Lisanti MP. Loss of Caveolin-3 induces a lactogenic microenvironment that is protective against mammary tumor formation. *Am J Path* 2009; **174**: 613–629.
28. Taylor IW, Linding R, Warde-Farley D, Liu YM, Pesquita C, Faria D, Bull S, Pawson T, Morris Q, Wrana JL. Dynamic modularity in protein interaction networks predicts breast cancer outcome. *Nat Biotechnol* 2009; **27**: 199–204.
29. Waltersson MA, Askmalms MS, Nordenskjold B, Fornander T, Skoog L, Stal O. Altered expression of cyclin E and the retinoblastoma protein influences the effect of adjuvant therapy in breast cancer. *Int J Oncol* 2009; **34**: 441–448.
30. Yang J, Bielenberg DR, Rodig SJ, Doiron R, Clifton MC, Kung AL, Strong RK, Zurakowski D, Moses MA. Lipocalin 2 promotes breast cancer progression. *Proc Natl Acad Sci U S A* 2009; **106**: 3913–3918.

Prepared by
R Sutherland
Cancer Research Program
Garvan Institute of Medical Research
Darlinghurst, NSW, Australia